CA2529057A1 - Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes - Google Patents
Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes Download PDFInfo
- Publication number
- CA2529057A1 CA2529057A1 CA002529057A CA2529057A CA2529057A1 CA 2529057 A1 CA2529057 A1 CA 2529057A1 CA 002529057 A CA002529057 A CA 002529057A CA 2529057 A CA2529057 A CA 2529057A CA 2529057 A1 CA2529057 A1 CA 2529057A1
- Authority
- CA
- Canada
- Prior art keywords
- antigen
- peptide
- epitope
- hla
- response
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 153
- 230000028993 immune response Effects 0.000 title claims abstract description 87
- 230000001225 therapeutic effect Effects 0.000 title abstract description 7
- 230000000069 prophylactic effect Effects 0.000 title abstract description 6
- 239000000203 mixture Substances 0.000 claims abstract description 92
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 256
- 108091007433 antigens Proteins 0.000 claims description 164
- 102000036639 antigens Human genes 0.000 claims description 164
- 239000000427 antigen Substances 0.000 claims description 162
- 210000004027 cell Anatomy 0.000 claims description 84
- 230000003053 immunization Effects 0.000 claims description 82
- 238000002649 immunization Methods 0.000 claims description 76
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 70
- 230000004044 response Effects 0.000 claims description 66
- 230000002163 immunogen Effects 0.000 claims description 57
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 56
- 239000013612 plasmid Substances 0.000 claims description 50
- 210000001165 lymph node Anatomy 0.000 claims description 41
- 239000002671 adjuvant Substances 0.000 claims description 37
- 102000004127 Cytokines Human genes 0.000 claims description 33
- 108090000695 Cytokines Proteins 0.000 claims description 33
- 241000124008 Mammalia Species 0.000 claims description 33
- 206010028980 Neoplasm Diseases 0.000 claims description 33
- 238000002347 injection Methods 0.000 claims description 33
- 239000007924 injection Substances 0.000 claims description 33
- 150000007523 nucleic acids Chemical class 0.000 claims description 31
- 102000039446 nucleic acids Human genes 0.000 claims description 29
- 108020004707 nucleic acids Proteins 0.000 claims description 29
- 229920001184 polypeptide Polymers 0.000 claims description 27
- 239000013598 vector Substances 0.000 claims description 27
- 241000700605 Viruses Species 0.000 claims description 25
- 230000005867 T cell response Effects 0.000 claims description 24
- 210000004324 lymphatic system Anatomy 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 108020000411 Toll-like receptor Proteins 0.000 claims description 21
- 102000002689 Toll-like receptor Human genes 0.000 claims description 21
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 16
- 210000003162 effector t lymphocyte Anatomy 0.000 claims description 16
- 239000003446 ligand Substances 0.000 claims description 15
- 230000002434 immunopotentiative effect Effects 0.000 claims description 14
- 230000001939 inductive effect Effects 0.000 claims description 14
- 238000003556 assay Methods 0.000 claims description 13
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 12
- 241000894006 Bacteria Species 0.000 claims description 12
- 230000001105 regulatory effect Effects 0.000 claims description 12
- 238000001802 infusion Methods 0.000 claims description 11
- 102000019034 Chemokines Human genes 0.000 claims description 10
- 108010012236 Chemokines Proteins 0.000 claims description 10
- 230000000091 immunopotentiator Effects 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 230000001717 pathogenic effect Effects 0.000 claims description 10
- 230000000770 proinflammatory effect Effects 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 9
- 244000052769 pathogen Species 0.000 claims description 8
- 239000013603 viral vector Substances 0.000 claims description 8
- 210000002421 cell wall Anatomy 0.000 claims description 7
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 claims description 7
- 208000027866 inflammatory disease Diseases 0.000 claims description 7
- 101100462972 Mus musculus Pcdh8 gene Proteins 0.000 claims description 6
- 230000003416 augmentation Effects 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 6
- 230000003308 immunostimulating effect Effects 0.000 claims description 6
- 230000001506 immunosuppresive effect Effects 0.000 claims description 6
- 210000005170 neoplastic cell Anatomy 0.000 claims description 6
- 210000003289 regulatory T cell Anatomy 0.000 claims description 6
- 230000003614 tolerogenic effect Effects 0.000 claims description 6
- 102000001327 Chemokine CCL5 Human genes 0.000 claims description 5
- 108010055166 Chemokine CCL5 Proteins 0.000 claims description 5
- 238000002784 cytotoxicity assay Methods 0.000 claims description 5
- 231100000263 cytotoxicity test Toxicity 0.000 claims description 5
- 210000002751 lymph Anatomy 0.000 claims description 5
- 230000000813 microbial effect Effects 0.000 claims description 5
- 102000003814 Interleukin-10 Human genes 0.000 claims description 4
- 108090000174 Interleukin-10 Proteins 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 102000007863 pattern recognition receptors Human genes 0.000 claims description 4
- 108010089193 pattern recognition receptors Proteins 0.000 claims description 4
- 102000005962 receptors Human genes 0.000 claims description 4
- 108020003175 receptors Proteins 0.000 claims description 4
- XEDONBRPTABQFB-UHFFFAOYSA-N 4-[(2-formyl-3-hydroxyphenoxy)methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1COC1=CC=CC(O)=C1C=O XEDONBRPTABQFB-UHFFFAOYSA-N 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 3
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims description 3
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims description 3
- 108010002616 Interleukin-5 Proteins 0.000 claims description 3
- 102000029797 Prion Human genes 0.000 claims description 3
- 108091000054 Prion Proteins 0.000 claims description 3
- 230000003190 augmentative effect Effects 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- 229950009795 tucaresol Drugs 0.000 claims description 3
- PIGTXFOGKFOFTO-FVFWYJKVSA-N (2S,3S,4S,5R,6R)-6-[[(3S,4S,4aR,6aR,6bS,8R,8aR,12aS,14aR,14bR)-8a-carboxy-4-formyl-8-hydroxy-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound O([C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)C[C@@H](O)[C@]1(CCC(C[C@H]14)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O PIGTXFOGKFOFTO-FVFWYJKVSA-N 0.000 claims description 2
- 206010061309 Neoplasm progression Diseases 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 239000006166 lysate Substances 0.000 claims description 2
- 238000003909 pattern recognition Methods 0.000 claims description 2
- 230000005751 tumor progression Effects 0.000 claims description 2
- 238000011510 Elispot assay Methods 0.000 claims 1
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 77
- 108020004414 DNA Proteins 0.000 description 62
- 108010058607 HLA-B Antigens Proteins 0.000 description 53
- 102000006390 HLA-B Antigens Human genes 0.000 description 53
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 36
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 34
- 238000003199 nucleic acid amplification method Methods 0.000 description 31
- 108010010995 MART-1 Antigen Proteins 0.000 description 30
- 241001465754 Metazoa Species 0.000 description 30
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 28
- 230000003321 amplification Effects 0.000 description 27
- 108010075704 HLA-A Antigens Proteins 0.000 description 26
- 102000011786 HLA-A Antigens Human genes 0.000 description 26
- 230000006698 induction Effects 0.000 description 26
- 230000036039 immunity Effects 0.000 description 21
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 15
- 101000986084 Homo sapiens HLA class I histocompatibility antigen, C alpha chain Proteins 0.000 description 15
- 101000880770 Homo sapiens Protein SSX2 Proteins 0.000 description 15
- 102100037686 Protein SSX2 Human genes 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 210000004988 splenocyte Anatomy 0.000 description 13
- 229960005486 vaccine Drugs 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 12
- 238000010186 staining Methods 0.000 description 12
- 230000008569 process Effects 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 10
- 210000000952 spleen Anatomy 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 230000001461 cytolytic effect Effects 0.000 description 9
- 239000012636 effector Substances 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 8
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 8
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 8
- 108091008874 T cell receptors Proteins 0.000 description 8
- 230000000890 antigenic effect Effects 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 230000004043 responsiveness Effects 0.000 description 8
- 108020004511 Recombinant DNA Proteins 0.000 description 7
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 210000005210 lymphoid organ Anatomy 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- POVNCJSPYFCWJR-USZUGGBUSA-N (4s)-4-[[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-[(2s)-2-[[2-[(2s)-2-[[(2s)-1-[[(2s,3r)-1-[[(1s)-1-carboxy-2-methylpropyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1- Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O)C1=CC=C(O)C=C1 POVNCJSPYFCWJR-USZUGGBUSA-N 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 6
- -1 for example Proteins 0.000 description 6
- 238000009169 immunotherapy Methods 0.000 description 6
- 230000003389 potentiating effect Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 208000037581 Persistent Infection Diseases 0.000 description 5
- 210000000612 antigen-presenting cell Anatomy 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 230000015654 memory Effects 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 230000002688 persistence Effects 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 230000003362 replicative effect Effects 0.000 description 5
- 238000012384 transportation and delivery Methods 0.000 description 5
- 101100494773 Caenorhabditis elegans ctl-2 gene Proteins 0.000 description 4
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 4
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 230000006054 immunological memory Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 210000005212 secondary lymphoid organ Anatomy 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 3
- 108010041986 DNA Vaccines Proteins 0.000 description 3
- 229940021995 DNA vaccine Drugs 0.000 description 3
- 102100032484 Down syndrome critical region protein 8 Human genes 0.000 description 3
- 101001016533 Homo sapiens Down syndrome critical region protein 8 Proteins 0.000 description 3
- 101000971521 Homo sapiens Kinetochore scaffold 1 Proteins 0.000 description 3
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 3
- 101001005717 Homo sapiens Melanoma-associated antigen 12 Proteins 0.000 description 3
- 101001057156 Homo sapiens Melanoma-associated antigen C2 Proteins 0.000 description 3
- 101001114051 Homo sapiens P antigen family member 5 Proteins 0.000 description 3
- 101000596845 Homo sapiens Testis-expressed protein 15 Proteins 0.000 description 3
- 102100021464 Kinetochore scaffold 1 Human genes 0.000 description 3
- 102100033467 L-selectin Human genes 0.000 description 3
- 102000016200 MART-1 Antigen Human genes 0.000 description 3
- 102000043129 MHC class I family Human genes 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- 102100025084 Melanoma-associated antigen 12 Human genes 0.000 description 3
- 102100027252 Melanoma-associated antigen C2 Human genes 0.000 description 3
- 102100023238 P antigen family member 5 Human genes 0.000 description 3
- 102100035116 Testis-expressed protein 15 Human genes 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000002975 chemoattractant Substances 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000003292 diminished effect Effects 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 210000003071 memory t lymphocyte Anatomy 0.000 description 3
- 238000011330 nucleic acid test Methods 0.000 description 3
- 230000000737 periodic effect Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000037452 priming Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 102100035565 B melanoma antigen 2 Human genes 0.000 description 2
- 102100035527 B melanoma antigen 3 Human genes 0.000 description 2
- 102100035567 B melanoma antigen 4 Human genes 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 2
- 102100039510 Cancer/testis antigen 2 Human genes 0.000 description 2
- 102100039361 Chondrosarcoma-associated gene 2/3 protein Human genes 0.000 description 2
- 102100025571 Cutaneous T-cell lymphoma-associated antigen 1 Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102100039701 G antigen 2B/2C Human genes 0.000 description 2
- 102100040003 G antigen 2D Human genes 0.000 description 2
- 102100039699 G antigen 4 Human genes 0.000 description 2
- 102100039713 G antigen 6 Human genes 0.000 description 2
- 102100040578 G antigen 7 Human genes 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 2
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 2
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 2
- 108010078301 HLA-B*07:02 antigen Proteins 0.000 description 2
- 108010024164 HLA-G Antigens Proteins 0.000 description 2
- 101000874318 Homo sapiens B melanoma antigen 2 Proteins 0.000 description 2
- 101000874317 Homo sapiens B melanoma antigen 3 Proteins 0.000 description 2
- 101000874320 Homo sapiens B melanoma antigen 4 Proteins 0.000 description 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 2
- 101000745414 Homo sapiens Chondrosarcoma-associated gene 2/3 protein Proteins 0.000 description 2
- 101000886151 Homo sapiens G antigen 2A Proteins 0.000 description 2
- 101000886136 Homo sapiens G antigen 4 Proteins 0.000 description 2
- 101000886141 Homo sapiens G antigen 6 Proteins 0.000 description 2
- 101000893968 Homo sapiens G antigen 7 Proteins 0.000 description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 2
- 101001005718 Homo sapiens Melanoma-associated antigen 2 Proteins 0.000 description 2
- 101001005719 Homo sapiens Melanoma-associated antigen 3 Proteins 0.000 description 2
- 101001005722 Homo sapiens Melanoma-associated antigen 6 Proteins 0.000 description 2
- 101001036688 Homo sapiens Melanoma-associated antigen B1 Proteins 0.000 description 2
- 101001036686 Homo sapiens Melanoma-associated antigen B2 Proteins 0.000 description 2
- 101001036675 Homo sapiens Melanoma-associated antigen B6 Proteins 0.000 description 2
- 101001057159 Homo sapiens Melanoma-associated antigen C3 Proteins 0.000 description 2
- 101000880769 Homo sapiens Protein SSX1 Proteins 0.000 description 2
- 101000880771 Homo sapiens Protein SSX3 Proteins 0.000 description 2
- 101000880774 Homo sapiens Protein SSX4 Proteins 0.000 description 2
- 101000825253 Homo sapiens Sperm protein associated with the nucleus on the X chromosome A Proteins 0.000 description 2
- 101000825254 Homo sapiens Sperm protein associated with the nucleus on the X chromosome B1 Proteins 0.000 description 2
- 101000825248 Homo sapiens Sperm protein associated with the nucleus on the X chromosome C Proteins 0.000 description 2
- 101000889756 Homo sapiens Tudor domain-containing protein 1 Proteins 0.000 description 2
- 101000835790 Homo sapiens Tudor domain-containing protein 6 Proteins 0.000 description 2
- 101000814497 Homo sapiens X antigen family member 3 Proteins 0.000 description 2
- 101000856240 Homo sapiens cTAGE family member 2 Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 102000000743 Interleukin-5 Human genes 0.000 description 2
- 102100025081 Melanoma-associated antigen 2 Human genes 0.000 description 2
- 102100025082 Melanoma-associated antigen 3 Human genes 0.000 description 2
- 102100025075 Melanoma-associated antigen 6 Human genes 0.000 description 2
- 102100039477 Melanoma-associated antigen B1 Human genes 0.000 description 2
- 102100039479 Melanoma-associated antigen B2 Human genes 0.000 description 2
- 102100039483 Melanoma-associated antigen B6 Human genes 0.000 description 2
- 102100027248 Melanoma-associated antigen C3 Human genes 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 241001631646 Papillomaviridae Species 0.000 description 2
- 102100037687 Protein SSX1 Human genes 0.000 description 2
- 102100037726 Protein SSX3 Human genes 0.000 description 2
- 102100037727 Protein SSX4 Human genes 0.000 description 2
- 102100022327 Sperm protein associated with the nucleus on the X chromosome A Human genes 0.000 description 2
- 102100022326 Sperm protein associated with the nucleus on the X chromosome B1 Human genes 0.000 description 2
- 102100022322 Sperm protein associated with the nucleus on the X chromosome C Human genes 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 102100040192 Tudor domain-containing protein 1 Human genes 0.000 description 2
- 102100026366 Tudor domain-containing protein 6 Human genes 0.000 description 2
- 102100039491 X antigen family member 3 Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000009093 first-line therapy Methods 0.000 description 2
- 244000144993 groups of animals Species 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000000367 immunologic factor Substances 0.000 description 2
- 230000001024 immunotherapeutic effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 244000000056 intracellular parasite Species 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 238000009966 trimming Methods 0.000 description 2
- 230000001173 tumoral effect Effects 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 description 1
- 101150109698 A2 gene Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- PIGTXFOGKFOFTO-PPEDVFHSSA-N CC1(C)CC[C@@]2([C@H](O)C[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CCC(O[C@@H]6O[C@@H]([C@@H](O)[C@H](O)[C@H]6O)C(O)=O)[C@@](C)(C=O)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O Chemical compound CC1(C)CC[C@@]2([C@H](O)C[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CCC(O[C@@H]6O[C@@H]([C@@H](O)[C@H](O)[C@H]6O)C(O)=O)[C@@](C)(C=O)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O PIGTXFOGKFOFTO-PPEDVFHSSA-N 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 102100039717 G antigen 1 Human genes 0.000 description 1
- 101710098476 G antigen 2D Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 108010073434 HLA-A*02:09 antigen Proteins 0.000 description 1
- 102220372951 HLA-A*3101 Human genes 0.000 description 1
- 108010018475 HLA-A31 antigen Proteins 0.000 description 1
- 102220391613 HLA-B*2702 Human genes 0.000 description 1
- 108010054198 HLA-B*27:05 antigen Proteins 0.000 description 1
- 108010030569 HLA-B*27:09 antigen Proteins 0.000 description 1
- 108010028440 HLA-B*46:01 antigen Proteins 0.000 description 1
- 108010017588 HLA-B*52:01 antigen Proteins 0.000 description 1
- 108010037618 HLA-C*08 antigen Proteins 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 101000889345 Homo sapiens Cancer/testis antigen 2 Proteins 0.000 description 1
- 101000886137 Homo sapiens G antigen 1 Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 101001005724 Homo sapiens Melanoma-associated antigen 9 Proteins 0.000 description 1
- 101001036406 Homo sapiens Melanoma-associated antigen C1 Proteins 0.000 description 1
- 101001057137 Homo sapiens Melanoma-associated antigen E1 Proteins 0.000 description 1
- 101000745415 Homo sapiens Putative chondrosarcoma-associated gene 1 protein Proteins 0.000 description 1
- 101001094545 Homo sapiens Retrotransposon-like protein 1 Proteins 0.000 description 1
- 101000825249 Homo sapiens Sperm protein associated with the nucleus on the X chromosome D Proteins 0.000 description 1
- 101000666379 Homo sapiens Transcription factor Dp family member 3 Proteins 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- 101000814512 Homo sapiens X antigen family member 1 Proteins 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 101100048372 Human cytomegalovirus (strain AD169) H301 gene Proteins 0.000 description 1
- 101100048373 Human cytomegalovirus (strain Merlin) UL18 gene Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100037924 Insulin-like growth factor 2 mRNA-binding protein 1 Human genes 0.000 description 1
- 101710126181 Insulin-like growth factor 2 mRNA-binding protein 1 Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 102100022430 Melanocyte protein PMEL Human genes 0.000 description 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 1
- 102100025079 Melanoma-associated antigen 9 Human genes 0.000 description 1
- 102100039447 Melanoma-associated antigen C1 Human genes 0.000 description 1
- 206010068052 Mosaicism Diseases 0.000 description 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 1
- 101100023550 Mycobacterium bovis (strain ATCC BAA-935 / AF2122/97) cmaD gene Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 102000036673 PRAME Human genes 0.000 description 1
- 108060006580 PRAME Proteins 0.000 description 1
- 101100161152 Pan troglodytes Patr-A gene Proteins 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 101150098008 Patr-A gene Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 description 1
- 101800001357 Potential peptide Proteins 0.000 description 1
- 102400000745 Potential peptide Human genes 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 102100039359 Putative chondrosarcoma-associated gene 1 protein Human genes 0.000 description 1
- 241000220259 Raphanus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102100022325 Sperm protein associated with the nucleus on the X chromosome D Human genes 0.000 description 1
- 101800001271 Surface protein Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 101150037769 TRX2 gene Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 102100038129 Transcription factor Dp family member 3 Human genes 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 102100039490 X antigen family member 1 Human genes 0.000 description 1
- 102100039492 X antigen family member 2 Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 239000012615 aggregate Substances 0.000 description 1
- 230000003092 anti-cytokine Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000012911 assay medium Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 108010007811 human immunodeficiency virus p17 gag peptide Proteins 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 101150024128 mmaA1 gene Proteins 0.000 description 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002159 nanocrystal Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000007112 pro inflammatory response Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 101150047061 tag-72 gene Proteins 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 230000009258 tissue cross reactivity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47939303P | 2003-06-17 | 2003-06-17 | |
| US60/479,393 | 2003-06-17 | ||
| PCT/US2004/019546 WO2005002621A2 (en) | 2003-06-17 | 2004-06-17 | Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2529057A1 true CA2529057A1 (en) | 2005-01-13 |
Family
ID=33563795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002529057A Abandoned CA2529057A1 (en) | 2003-06-17 | 2004-06-17 | Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20050079152A1 (https=) |
| EP (3) | EP2356999A1 (https=) |
| JP (2) | JP5127224B2 (https=) |
| AT (1) | ATE476196T1 (https=) |
| AU (1) | AU2004253479B9 (https=) |
| CA (1) | CA2529057A1 (https=) |
| DE (1) | DE602004028468D1 (https=) |
| DK (1) | DK1635863T3 (https=) |
| ES (1) | ES2350043T3 (https=) |
| MX (1) | MXPA05013973A (https=) |
| PL (1) | PL1635863T3 (https=) |
| WO (1) | WO2005002621A2 (https=) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6727230B1 (en) * | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
| US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
| US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6977074B2 (en) * | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
| US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
| US6693086B1 (en) * | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
| ES2572834T3 (es) | 1999-02-17 | 2016-06-02 | Csl Limited | Complejos inmunogénicos y métodos relacionados con los mismos |
| NZ520976A (en) * | 1999-11-19 | 2005-01-28 | Csl Ltd | Vaccine compositions |
| US20040131628A1 (en) * | 2000-03-08 | 2004-07-08 | Bratzler Robert L. | Nucleic acids for the treatment of disorders associated with microorganisms |
| KR100917101B1 (ko) * | 2000-08-04 | 2009-09-15 | 도요 보세키 가부시키가이샤 | 플렉시블 금속적층체 및 그 제조방법 |
| US7807803B2 (en) | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7576066B2 (en) * | 2002-07-03 | 2009-08-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7605138B2 (en) * | 2002-07-03 | 2009-10-20 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US20040053880A1 (en) * | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7569553B2 (en) * | 2002-07-03 | 2009-08-04 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| CN1753687A (zh) * | 2002-10-29 | 2006-03-29 | 科勒制药集团股份有限公司 | Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用 |
| AU2004226605A1 (en) * | 2003-04-02 | 2004-10-14 | Coley Pharmaceutical Group, Ltd. | Immunostimulatory nucleic acid oil-in-water formulations for topical application |
| US7178491B2 (en) * | 2003-06-05 | 2007-02-20 | Caterpillar Inc | Control system and method for engine valve actuator |
| US20060008468A1 (en) * | 2004-06-17 | 2006-01-12 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in diagnostics for various types of cancers |
| US20060159689A1 (en) * | 2004-06-17 | 2006-07-20 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in diagnostics for various types of cancers |
| CA2571168A1 (en) * | 2004-06-17 | 2006-01-26 | Mannkind Corporation | Mhc i-binding ssx-241-49 variants |
| US20050287068A1 (en) * | 2004-06-17 | 2005-12-29 | Bot Adrian I | Efficacy of active immunotherapy by integrating diagnostic with therapeutic methods |
| WO2007001448A2 (en) | 2004-11-04 | 2007-01-04 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
| EP1838338A2 (en) * | 2004-12-29 | 2007-10-03 | Mannkind Corporation | Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs |
| PL1833506T3 (pl) * | 2004-12-29 | 2016-01-29 | Mannkind Corp | Zastosowanie kompozycji zawierających różne antygeny związane z nowotworem jako szczepionek przeciwnowotworowych |
| JP2008526763A (ja) * | 2004-12-29 | 2008-07-24 | マンカインド コーポレイション | 予防又は治療目的のｍｈｃクラスｉ拘束性エピトープに対する免疫応答の誘導、増強及び保持方法 |
| CA2592972A1 (en) * | 2004-12-29 | 2006-07-06 | Mannkind Corporation | Methods to bypass cd+4 cells in the induction of an immune response |
| NZ564359A (en) * | 2005-06-17 | 2011-09-30 | Mannkind Corp | Analogs of pepetides corresponding to class I MHC-restricted T cell epitopes |
| SG162817A1 (en) * | 2005-06-17 | 2010-07-29 | Mannkind Corp | Methods and compositions.to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma |
| AU2006259221B8 (en) * | 2005-06-17 | 2013-02-07 | Mannkind Corporation | Multivalent entrain-and-amplify immunotherapeutics for carcinoma |
| KR20080030656A (ko) * | 2005-07-07 | 2008-04-04 | 콜레이 파마시티컬 그룹, 인코포레이티드 | 암 치료를 위한 항-ＣＴＬＡ-4 항체 및 ＣｐＧ-모티프-함유합성 올리고데옥시뉴클레오티드의 조합 요법 |
| EP1792627A1 (en) * | 2005-12-05 | 2007-06-06 | ImVisioN AG | Modulation of the immune response by administration of intralymphatic transduction allergen (ITAG-)-molecules |
| WO2007065633A1 (en) * | 2005-12-05 | 2007-06-14 | Imvision Ag | Modulation of the immune response by administration of intralymphatic transduction allergen (itag) -molecules |
| WO2007070682A2 (en) | 2005-12-15 | 2007-06-21 | Massachusetts Institute Of Technology | System for screening particles |
| US20090061478A1 (en) * | 2006-01-30 | 2009-03-05 | Lene Have Poulsen | High-Speed Quantification of Antigen Specific T-Cells in Whole Blood by Flow Cytometry |
| CA2648099C (en) * | 2006-03-31 | 2012-05-29 | The Brigham And Women's Hospital, Inc | System for targeted delivery of therapeutic agents |
| JP5630998B2 (ja) | 2006-05-15 | 2014-11-26 | マサチューセッツ インスティテュート オブ テクノロジー | 機能的粒子のためのポリマー |
| WO2007144772A2 (en) * | 2006-06-15 | 2007-12-21 | Novartis Ag | Adjuvant-sparing multi-dose influenza vaccination regimen |
| WO2007150030A2 (en) * | 2006-06-23 | 2007-12-27 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
| JP2009544610A (ja) * | 2006-07-14 | 2009-12-17 | マンカインド コーポレイション | 予防又は治療目的のためにｍｈｃクラスｉ拘束エピトープに対する免疫応答を引き出し、増強し、保持する方法 |
| WO2008019142A2 (en) * | 2006-08-04 | 2008-02-14 | Massachusetts Institute Of Technology | Oligonucleotide systems for targeted intracellular delivery |
| EP2134830A2 (en) | 2007-02-09 | 2009-12-23 | Massachusetts Institute of Technology | Oscillating cell culture bioreactor |
| CN103736086A (zh) * | 2007-02-15 | 2014-04-23 | 曼康公司 | 用于增强t细胞应答的方法 |
| WO2008116468A2 (en) | 2007-03-26 | 2008-10-02 | Dako Denmark A/S | Mhc peptide complexes and uses thereof in infectious diseases |
| CN101687022B (zh) * | 2007-03-26 | 2016-09-07 | 莱顿大学医学中心附属莱顿教学医院 | Prame衍生的肽以及包括该肽的免疫原组合物 |
| JP2010523595A (ja) * | 2007-04-04 | 2010-07-15 | マサチューセッツ インスティテュート オブ テクノロジー | ポリ（アミノ酸）ターゲッティング部分 |
| EP3620465B1 (en) | 2007-07-03 | 2025-02-19 | Dako Denmark A/S | Improved methods for generation, labeling and use of mhc multimers |
| US10611818B2 (en) | 2007-09-27 | 2020-04-07 | Agilent Technologies, Inc. | MHC multimers in tuberculosis diagnostics, vaccine and therapeutics |
| JP2011500569A (ja) | 2007-10-12 | 2011-01-06 | マサチューセッツ インスティテュート オブ テクノロジー | ワクチンナノテクノロジー |
| DK2254592T3 (da) | 2008-02-28 | 2019-09-09 | Dako Denmark As | MHC-multimerer til Borrelia-diagnostik og sygdom |
| WO2010009735A2 (en) | 2008-07-23 | 2010-01-28 | Dako Denmark A/S | Combinatorial analysis and repair |
| GB0817244D0 (en) | 2008-09-20 | 2008-10-29 | Univ Cardiff | Use of a protein kinase inhibitor to detect immune cells, such as T cells |
| US11992518B2 (en) | 2008-10-02 | 2024-05-28 | Agilent Technologies, Inc. | Molecular vaccines for infectious disease |
| WO2010037402A1 (en) | 2008-10-02 | 2010-04-08 | Dako Denmark A/S | Molecular vaccines for infectious disease |
| US8591905B2 (en) | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
| US8343498B2 (en) | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
| US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
| US8343497B2 (en) | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
| AU2010310468A1 (en) | 2009-10-23 | 2012-05-24 | Mannkind Corporation | Cancer immunotherapy and method of treatment |
| EA201390660A1 (ru) | 2010-11-05 | 2013-11-29 | Селекта Байосайенсиз, Инк. | Модифицированные никотиновые соединения и связанные способы |
| WO2020127222A2 (en) | 2018-12-17 | 2020-06-25 | Immudex Aps | Panel comprising borrelia mhc multimers |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2606601A (en) | 1948-12-14 | 1952-08-12 | Knoll Associates | Chair having a back rest in the form of a shell-like body |
| AU7983198A (en) * | 1997-06-23 | 1999-01-04 | Ludwig Institute For Cancer Research | Improved methods for inducing an immune response |
| ES2265165T3 (es) * | 1997-07-10 | 2007-02-01 | Mannkind Corporation | Dispositivo para inducir una respuesta ltc. |
| US6977074B2 (en) * | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
| US6709844B1 (en) | 2000-11-16 | 2004-03-23 | Mannkind Corporation | Avoidance of undesirable replication intermediates in plasmid propagation |
| US20030138808A1 (en) | 1998-02-19 | 2003-07-24 | Simard John J.L. | Expression vectors encoding epitopes of target-associated antigens |
| CA2388337C (en) * | 1999-10-22 | 2013-01-08 | Aventis Pasteur Limited | Method of inducing and/or enhancing an immune response to tumor antigens |
| US20030215425A1 (en) | 2001-12-07 | 2003-11-20 | Simard John J. L. | Epitope synchronization in antigen presenting cells |
| US6861234B1 (en) * | 2000-04-28 | 2005-03-01 | Mannkind Corporation | Method of epitope discovery |
| US6773695B2 (en) * | 2000-10-05 | 2004-08-10 | Mannkind Corporation | Modulation of allergic response |
| US7252824B2 (en) * | 2001-03-07 | 2007-08-07 | Mannkind Corporation | Anti-neovasculature preparations for cancer |
| CA2439111A1 (en) * | 2001-04-05 | 2002-10-17 | Chiron Corporation | Mucosal boosting following parenteral priming |
| WO2003008537A2 (en) | 2001-04-06 | 2003-01-30 | Mannkind Corporation | Epitope sequences |
| US7076244B2 (en) | 2001-07-23 | 2006-07-11 | Research In Motion Limited | System and method for pushing information to a mobile device |
| GB0118532D0 (en) * | 2001-07-30 | 2001-09-19 | Isis Innovation | Materials and methods relating to improved vaccination strategies |
| CN101024842A (zh) | 2001-11-07 | 2007-08-29 | 曼康公司 | 编码靶相关抗原表位的表达载体及其设计方法 |
| CA2467486A1 (en) * | 2001-11-30 | 2003-06-12 | Isis Innovation Limited | Vaccine |
| AU2003270311A1 (en) | 2002-09-06 | 2004-03-29 | Mannkind Corporation | Epitope sequences |
| US20060257416A1 (en) * | 2003-06-13 | 2006-11-16 | Palmowski J M | Materials and methods for improved vaccination |
| US9469902B2 (en) | 2014-02-18 | 2016-10-18 | Lam Research Corporation | Electroless deposition of continuous platinum layer |
| US9814289B2 (en) | 2015-04-08 | 2017-11-14 | Otter Products, Llc | Protective folio case for an electronic device |
| EP3636238B1 (en) | 2018-10-12 | 2021-04-28 | Liko Research & Development AB | Gates with transition ramps for overhead lifting rails |
-
2004
- 2004-06-17 DK DK04776760.3T patent/DK1635863T3/da active
- 2004-06-17 EP EP10180566A patent/EP2356999A1/en not_active Ceased
- 2004-06-17 EP EP04776760A patent/EP1635863B1/en not_active Expired - Lifetime
- 2004-06-17 CA CA002529057A patent/CA2529057A1/en not_active Abandoned
- 2004-06-17 EP EP10171754.4A patent/EP2246067B1/en not_active Expired - Lifetime
- 2004-06-17 PL PL04776760T patent/PL1635863T3/pl unknown
- 2004-06-17 ES ES04776760T patent/ES2350043T3/es not_active Expired - Lifetime
- 2004-06-17 JP JP2006517407A patent/JP5127224B2/ja not_active Expired - Fee Related
- 2004-06-17 AU AU2004253479A patent/AU2004253479B9/en not_active Ceased
- 2004-06-17 MX MXPA05013973A patent/MXPA05013973A/es active IP Right Grant
- 2004-06-17 US US10/871,707 patent/US20050079152A1/en not_active Abandoned
- 2004-06-17 WO PCT/US2004/019546 patent/WO2005002621A2/en not_active Ceased
- 2004-06-17 DE DE602004028468T patent/DE602004028468D1/de not_active Expired - Lifetime
- 2004-06-17 AT AT04776760T patent/ATE476196T1/de active
-
2012
- 2012-09-10 JP JP2012198859A patent/JP2013028619A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2246067A2 (en) | 2010-11-03 |
| JP2013028619A (ja) | 2013-02-07 |
| AU2004253479B2 (en) | 2011-09-01 |
| JP2007523863A (ja) | 2007-08-23 |
| MXPA05013973A (es) | 2006-03-02 |
| DK1635863T3 (da) | 2010-11-22 |
| EP2246067B1 (en) | 2017-02-15 |
| WO2005002621A3 (en) | 2005-08-04 |
| EP1635863A2 (en) | 2006-03-22 |
| ES2350043T3 (es) | 2011-01-17 |
| ATE476196T1 (de) | 2010-08-15 |
| US20050079152A1 (en) | 2005-04-14 |
| EP1635863B1 (en) | 2010-08-04 |
| WO2005002621A2 (en) | 2005-01-13 |
| JP5127224B2 (ja) | 2013-01-23 |
| AU2004253479A1 (en) | 2005-01-13 |
| AU2004253479B9 (en) | 2011-10-06 |
| EP2246067A3 (en) | 2011-07-13 |
| PL1635863T3 (pl) | 2011-01-31 |
| DE602004028468D1 (de) | 2010-09-16 |
| EP2356999A1 (en) | 2011-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2004253479B9 (en) | Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes | |
| IL184273A (en) | Use of entraining and amplifying compositions in the manufacture of a medicament for immunization and a set of immunogenic compositions for inducing an immune response in a mammal | |
| Bocchia et al. | Antitumor vaccination: where we stand | |
| Stevenson et al. | DNA fusion gene vaccines against cancer: from the laboratory to the clinic | |
| JP2019534308A (ja) | 免疫療法的腫瘍治療方法 | |
| CN101646455A (zh) | 用于癌症的治疗剂 | |
| BG62999B1 (bg) | Анти туморна ваксина и метод за нейното получаване | |
| Hermans et al. | Tumor-peptide-pulsed dendritic cells isolated from spleen or cultured in vitro from bone marrow precursors can provide protection against tumor challenge | |
| Hodge et al. | Vector-based delivery of tumor-associated antigens and T-cell co-stimulatory molecules in the induction of immune responses and anti-tumor immunity | |
| Weigel et al. | Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses | |
| US20220152167A1 (en) | Immunogenic formulations for treating cancer | |
| Najar et al. | Topical TLR9 agonists induce more efficient cross‐presentation of injected protein antigen than parenteral TLR9 agonists do | |
| AU2011213698B2 (en) | Method to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes | |
| HK1150232A (en) | Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes | |
| HK1161085A (en) | Compositions to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes | |
| Al Saihati | Overview of Dendritic Cell Vaccines as Effective Approaches in Cancer Immunotherapy. | |
| JP2008546788A (ja) | 前立腺癌に対するワクチンに関する方法及び組成物 | |
| HK1120722B (en) | The use of immunogenic composition in preparing a response and enhance the use of the reagent kit for immune responses | |
| Suresh et al. | Recent advances in immunotherapy of B-CLL using ex vivo modified dendritic cells | |
| US20180055920A1 (en) | Vaccine, therapeutic composition and methods for treating or inhibiting cancer | |
| Beverly et al. | Immunity and cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20170619 |